health-related quality of life (HRQOL) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after ≥ 2 prior therapies. This analysis evaluates the impact of Lonca on HRQOL, symptoms, and tolerability stratified by age group
Search Results
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
Alexander Spira, Laura Liao, Xiaolei Zhou, Bintu Sherif, Lei Chen, David Ungar, Eric Yu, John Radford, and Mehdi Hamadani
Updates in the Treatment of Multiple Myeloma
Presented by: Shaji K. Kumar
many new therapies for newly diagnosed and relapsed disease. Despite this, patients continue to relapse, and we continue to try to improve the treatments we use for patients at the time of diagnosis,” he said. Advances in Transplant-Eligible, Newly
Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance
Adalgisa Condoluci and Davide Rossi
variable (IGHV) genes. 17 Deletions of 17p13/ TP53 mutations occur in 10% of newly diagnosed CLL and progressive CLL requiring first treatment, and in 30% to 40% of cases of relapsed CLL ( Table 1 ). The TP53 gene may be inactivated by deletion and
Part 1: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™
Patients With Relapsed Hodgkin Lymphoma After Autologous Stem Cell Transplant in 5 European Countries Adeline Abbé, a Andrew Lee, a Alaa Hamed, a Frank Neumann, b Robert Olivares, a and Andreas Engert c a Sanofi, Global Evidence and Value
Survival in Patients With Sentinel Node–Positive Melanoma With Extranodal Extension
Andrea Maurichi, Francesco Barretta, Roberto Patuzzo, Rosalba Miceli, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Martina Angi, Francesco Baldo Lanza, Giuseppe Spadola, Mara Cossa, Francesco Nesa, Umberto Cortinovis, Laura Sala, Lorenza Di Guardo, Carolina Cimminiello, Michele Del Vecchio, Barbara Valeri, and Mario Santinami
-rank test. Median follow-up was estimated with the reverse Kaplan-Meier method using OS data. 19 The crude cumulative incidence (CCI) of local relapse, regional relapse, and distant metastasis was estimated in a competing risk setting using cumulative
Molecular Classification Improves Therapeutic Options for Infants and Young Children With Medulloblastoma
Aditi Bagchi, Sandeep K. Dhanda, Paige Dunphy, Edgar Sioson, and Giles W. Robinson
. However, these therapies had their drawbacks. Those who received focal RT often experienced a metastatic relapse. 29 , 30 The toxicity of HDC-AuSCR was responsible for approximately 10% to 14% of therapy-related deaths. 24 , 25 Leukoencephalopathic
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, and Hema Sundar
involved in the B-cell receptor pathway have demonstrated promising activity for the treatment of relapsed/refractory FL. CAR T-cell therapy has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights
Maintenance Therapy With Tyrosine Kinase Inhibitors After Transplant in Patients With Chronic Myeloid Leukemia
Merav Bar and Jerald Radich
Therefore, which patients with CML should be considered for allogeneic transplant? Not many. With imatinib, approximately 40% of patients will eventually discontinue therapy, either because of initial failure to achieve milestones, intolerance, or relapse
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Julie E. Chang, Beth Christian, Sven DeVos, Bhagirathbhai Dholaria, Luis E. Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Boyu Hu, Mark S. Kaminski, Yasmin Karimi, Christopher R. Kelsey, Rebecca King, Susan Krivacic, Ann S. LaCasce, Megan Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar
MCL with TP53 mutation, and aids in the selection of appropriate treatment, particularly if up-front HDT/ASCR is anticipated. 10 These NCCN Guidelines Insights discuss recent updates to the management of newly diagnosed and relapsed
Management of Patients With Advanced Melanoma
Presented by: Genevieve Boland
, hazard ratio; Ipi, ipilimumab; Nivo, nivolumab; NR, not reached; Pembro, pembrolizumab; RFS, relapse-free survival. In 2014, the CTLA-4 inhibitor ipilimumab became the first approved immunotherapy for the adjuvant treatment of melanoma, but its
